August 23, 2017 • lyfebulb.com
Lyfebulb, the company co-founded by Dr. Karin Hehenberger PhD, with Dr. Steve Squinto, Venture partner Orbimed and Riccardo Braglia, CEO Helsinn, is about to launch an early-stage Autoimmune Disease / Diabetes Innovation Venture Fund. The Scientific Advisory Board is chaired by Robert Langer PhD, David H. Koch Institue, MIT. Focused on breakthrough opportunities in autoimmune, insulin-dependent diabetes and other associated autoimmune diseases. Our goals are to deliver a superior return on investment. Full investment news article
March 14, 2017 • pehub.com
XYZ Ventures is seeking to raise $70 million for its maiden fund, according to an SEC filing. The newly formed firm was launched by Ross Fubini, a former venture partner at Canaan Partners. Full investment news article
Please select a file format in which you would like to recieve this signal report...